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Background: Intensity modulated arc therapy (IMAT) has been widely adopted for Stereotactic Body Radiotherapy
(SBRT) for lung cancer. While treatment dose is optimized and calculated on a static Computed Tomography (CT)
image, the effect of the interplay between the target and linac multi-leaf collimator (MLC) motion is not well
described and may result in deviations between delivered and planned dose. In this study, we investigated the
dosimetric consequences of the inter-play effect on target and organs at risk (OAR) by simulating dynamic dose
delivery using dynamic CT datasets.
Methods: Fifteen stage I non-small cell lung cancer (NSCLC) patients with greater than 10 mm tumor motion
treated with SBRT in 4 fractions to a dose of 50 Gy were retrospectively analyzed for this study. Each IMAT plan was
initially optimized using two arcs. Simulated dynamic delivery was performed by associating the MLC leaf position,
gantry angle and delivered beam monitor units (MUs) for each control point with different respiratory phases of the
4D-CT using machine delivery log files containing time stamps of the control points. Dose maps associated with each
phase of the 4D-CT dose were calculated in the treatment planning system and accumulated using deformable image
registration onto the exhale phase of the 4D-CT. The original IMAT plans were recalculated on the exhale phase of the
CT for comparison with the dynamic simulation.
Results: The dose coverage of the PTV showed negligible variation between the static and dynamic simulation. There
was less than 1.5% difference in PTV V95% and V90%. The average inter-fraction and cumulative dosimetric effects
among all the patients were less than 0.5% for PTV V95% and V90% coverage and 0.8 Gy for the OARs. However, in
patients where target is close to the organs, large variations were observed on great vessels and bronchus for as much
as 4.9 Gy and 7.8 Gy.
Conclusions: Limited variation in target dose coverage and OAR constraints were seen for each SBRT fraction as well
as over all four fractions. Large dose variations were observed on critical organs in patients where these organs were
closer to the target.
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Stereotactic body radiation therapy (SBRT) has been in-
creasingly employed in the treatment of medically inop-
erable early stage non-small cell lung cancer (NSCLC).
SBRT involves hypofractionation to deliver a large dose
per fraction in a small number (usually 1–5) of treat-
ments to the target volume while minimizing normal* Correspondence: zouwe@cinj.rutgers.edu
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unless otherwise stated.tissue exposure. Studies have suggested that SBRT pro-
vides high rates of local control with few high grade tox-
icities [1]. Treatment plans are designed to provide
sharp dose fall-off outside the target to avoid normal tis-
sue toxicity. Intensity modulated arc therapy (IMAT) is
a newer treatment modality that can deliver highly con-
formal dose distributions with fewer monitor units than
intensity modulated radiation therapy (IMRT) [2]. IMAT
delivers an optimized plan comprising of one or multiple
arcs with continuous gantry rotation while modulating
the fluence with the multi-leaf collimator (MLC) [3]. It. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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reduced treatment time compared with IMRT and 3D-
conformal treatment [5-8].
For the treatment of lung and abdominal tumors, the
effect of respiratory motion on both the target and or-
gans at risk (OAR) is a source of concern. Multiple
methods that have been proposed to manage tumor
motion include tumor tracking, breathing control,
forced shallow breathing and gated delivery [9]. One
way to account for tumor motion [10,11] is to create
margins using an internal target volume (ITV) that en-
compasses the motion envelope of the tumor derived
from a respiratory-gated computed tomography (4D-
CT) [12]. During IMRT and IMAT delivery, the inter-
play between the target and the multi-leaf collimator
motion can lead to dose discrepancies in conventional
fractionation scheme of about two Gy per fraction.
Studies [13-16] have shown that under multiple fields
and after a large number of fractions, the interplay ef-
fect in IMRT delivery results in a smeared dose distri-
bution where the standard deviation of the dose is
generally within 1% of the expected value [13].
In contrast to traditional fractionation, the dose aver-
aging effect in SBRT IMAT delivery using hypofractio-
nation is expected to be smaller given the limited
number of fractions. However, limited data exist asses-
sing the dosimetric consequence from the interplay
among the fluence, gantry and MLC motion. Experi-
mental studies have been performed to examine the
impact of this interplay effect using film dosimetry and
phantoms [17-19]. Patient-specific study is desirable
and can be accomplished using computer simulation of
the interplay effect. Kuo et al. [20] studied a single arc
therapy on hepatic cancer patients by warping the dose
distribution of multiple 4D CT phases to a reference
CT image using deformable image registration. Rao
et al. [21] studied volumetric-modulated arc therapy
(VMAT) using a single arc for a three fraction SBRT
treatment regimen (60 Gy total) on a 80-leaf MLC
Elekta linac (Elekta AB, Stockholm, Sweden) for lung
cancer. In both cases, less than 1% difference was
found on target dose distribution between the 4D cal-
culation and the 3D calculation. In this study, we in-
vestigated the interplay effect on a four fraction IMAT
RapidArc SBRT lung cancer treatment regimen (50 Gy
total) using two arcs on a Varian linac with a 120-leaf
MLC (Varian Medical Systems, Palo Alto, CA). Ma-
chine delivery data files were used to correlate the
respiratory phase with the plan control points. Using
4D CT and deformable image registration tools, dy-
namic simulation of lung SBRT treatments was used to
investigate the cumulative as well as inter-fraction dose
deviations on target and organ at risk (OAR) dose
distributions.Methods and materials
Patient selection and simulation
Fifteen lung cancer patients with stage I peripheral tu-
mors treated with SBRT were retrospectively selected
for this study approved by the Institutional Review
Board (University of Pennsylvania). Patients were simu-
lated on either a Philips Gemini Big Bore PET/CT
scanner (Philips Healthcare, Andover, MA) or a Sie-
mens Sensation Open CT scanner (Siemens Medical
Solutions USA, Inc. Malvern, PA). Both scanners were
equipped with the Varian Real-time Position Manage-
ment (RPM) system (Varian Medical Systems, Palo
Alto, CA) for 4D scans. The CT images acquired
included a free-breathing CT and a 4D CT image set.
Abdominal compression was not employed. The target
motion throughout the respiratory cycle was analyzed
in three directions: superior-inferior, left-right, and
anterior-posterior. As the interplay effect is expected to
potentially have a larger effect on the delivered dose
when there is large motion, only patients with
>10 mm GTV motion in the superior-inferior direc-
tion were selected for this study. The mean motion of
this cohort of patients was 12.9 mm with 2.7 mm
standard deviation.
3D RapidArc plans
The initial patient RapidArc plans were optimized
using the Eclipse treatment planning system (Varian
Medical Systems, Palo Alto, CA). The GTV was deter-
mined on each respiratory phase of the 4D CT and
used to generate the ITV that enclosed all of the iden-
tified GTVs from each respiratory phase. A 3 mm uni-
form expansion margin was applied to the ITV to
obtain the PTV. The RapidArc plans utilized two co-
planar arcs with reciprocal end points typically span-
ning approximately 200 degrees around the ipsilateral
lung and a dose of 50 Gy in four fractions was deliv-
ered to the PTV. The plans were optimized on the
free-breathing CT image in Eclipse and the anisotropic
analytical algorithm (AAA) was used to calculate dose.
These plans met the PTV and OAR constraints that
were adopted from RTOG 0915 [22].
4D RapidArc plan partitioning
In order to simulate respiratory motion effects on Rapi-
dArc beam delivery, the plan control points which define
the gantry angle, MLC leaf position, MUs of the original
plan have to be associated with the respiratory phase.
These control points were optimized to achieve the de-
sired dose distribution while satisfying the machine
hardware constraints [22]. As each arc of a SBRT plan
was delivered through several breathing periods (range
2.2-4.3 seconds), association of control points to the re-
spiratory phase of a 4D CT was made by making the
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measured during the 4D CT, was periodic and represen-
tative of patient respiration during RapidArc delivery.
Using the timestamps within the Varian linac Dynalog
files which recorded the MLC leaf positions and gantry
angle at every 50 ms time interval during beam delivery,
each arc was partitioned into a series of smaller sub-
arcs that contained only beams that were correlated to a
particular respiratory phase.
The control points of each arc can be expressed math-
ematically as
Corg ¼ Ci : θi;MLCi;j;MUi; ti
 
; Ci ∈I0
where I0 is the collection of control points in the ori-
ginal plan; θ i is the gantry angle at ith control point,
MLCi,j is the jth leaf sequence of the two MLC banks,
MUi is the delivered MU at the ith control point; ti is
the time from the start of the arc delivery to the time
the Ci control point is executed. The time values were
extracted from the patient delivery Dynalog files. These
control points were indicated as short lines along the
original arcs in Figure 1a as an example. To associate
the arc with the breathing cycles, the arc was first di-
vided into time intervals Δt = TR/N where TR is the pa-
tient respiratory period and N is the number of
breathing phases used. Representatively four (N = 4) re-
spiratory phases, namely, the 0% (maximum inhal-
ation), 25%, 50% (maximum exhalation), and 75%, were
adopted in this study. Additional control points at the
transition between respiratory phases were inserted
into the arc to represent the exact start and end points
of each respiratory phase. The parameters of these add-
itional control points were derived from time-based lin-
ear interpolation of the two adjacent original control
points. The total control points then consisted of a col-
lection of the original and interpolated control points,a)
Figure 1 Original and partitioned RapidArc plans. a) The original Rapid
along the arcs. b) A partitioned RapidArc plan with a subset of original contro
phase. This partial plan is used to compute the dose delivered to the patientCtot ¼ Ci : θi;MLCi;j;MUi; ti
 
; Ci ∈ I 0;
where I’ is the collection of the original and the add-
itional control points. This cohort of control points Ctot
were then partitioned and reassembled into four sub-
arcs that were associated with each of the four respira-
tory phases,
Ctotn ¼ fCi : θi;MLCi;j;MUi; ti; at ti∈½M⋅TR
þ n−1ð ÞTR=N ;M⋅TR þ nTR=N g; Ci ∈ I 0; n
¼ 1…N
where M is an integer representing the number of re-
spiratory cycles that have elapsed during the delivery of
the arc. Control points that were outside of the corre-
sponding respiratory phase had zero MUs and were ex-
cluded. An example of a partitioned plan associated with
one CT phase was shown in Figure 1b. Plan partitioning
was performed using MATLAB (MathWorks, Inc.
Natick, MA) software and re-imported into the treat-
ment planning system for 4D dose calculation.
4D Dose calculation
D.1. Respiratory phase initialization and 4D dose
accumulation
A random initial respiratory phase n0_k was selected for
each arc in fraction k. The dose delivered to each re-
spiratory phase n at each fraction Dn,n0_k was forward
calculated using the partitioned plans on the associated
phase of the 4D CT. Figure 2 showed a flow chart illus-
trating the process. The maximum exhalation phase
(50%) was chosen as the reference CT phase for dose
accumulation. Each phase of the 4D CT image set was
registered to the reference CT using MIM Maestro
(MIM Software Inc., Cleveland, OH) deformable image
registration software. The deformation vector fields
from the source to target images can be written as
FCTn->CT50%, where n = 1…N. The deformation vectorb)
Arc plan and corresponding control points indicated by short lines
l points and interpolated control points associated with one respiratory
at one respiratory phase.
Figure 2 Flow chart of plan partitioning, dose calculation and dose accumulation using 4D CT images. Here “Part. Plan” represents
“Partitioned Plan”, “Def. Reg.” represents “Deformable Registration”.
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doses onto the exhalation CT image and subsequently





The above process was repeated for each fraction and
the cumulative 4D dose through the SBRT treatment to
the patient can be obtained by summing the fractional







D.2. Comparison between 3D planned and cumulative
4D doses
The dose statistics were compared between the initial
3D planned dose and the cumulative 4D dose calculated
from the 4D-CT image sets. The PTV in the original 3D
plans was generated from the ITV. The PTV defined onTable 1 Effect of motion on tumor target dose distribution in






PTV V90% −0.48% (−1.44%, 0.25%) 0.20
PTV V95% −0.10% (−1.22%, 1.31%) 0.12
PTV V105% −5.04% (−13.88%, 9.71%) 1.66
V_Presp. Iso./V_PTV −0.15 (−0.31, −0.01) 0.04
V_50% Pres. Iso./V_PTV −0.14 (−0.68, 0.06) 0.05
D2cm −0.22 Gy (−2.20 Gy, 1.70 Gy) 0.45
The mean values are cumulative dose differences averaged over all patients. The m
variations among four fractions over all patients.the 4D dose calculations was generated directly from the
expansion of the GTV in the maximum exhalation phase
of the 4D CT by the same physician. In the 4D dose calcu-
lation, GTV motion was already taken into account by the
deformable image registration and the modified 4D PTV
represents the PTV in that phase of the breathing cycle
with setup error margin only. This was done to isolate the
interplay effect more clearly for dosimetric comparison. If
the original PTV, which included the ITV, was warped into
a single phase, the coverage of the warped PTV will de-
crease even if there were no inter-play effects because dose
warping was equivalent to evaluation in a frame of refer-
ence with no motion. The same set of organ at risks was
also re-contoured by the same physician in the maximum
exhalation phase of 4D-CT.
D.3. 4D Inter-fraction and cumulative inter-play effects
Inter-fraction effects were simulated using a different
initialization phase of the 4D CT in the 4D dose calcula-
tion. This effect was evaluated by comparing the variation




Difference between cumulative 4D doses with
and without motion
Mean (min, max)
% (0.00%,1.89%) −0.35% (−1.22%, 0.83%)
% (0.00%, 1.38%) −0.26% (−1.06%, 1.97%)
% (0.00%, 6.87%) 2.75% (−5.90%, 4.65%)
(0.00,0.15) −0.30 (−0.91, −0.01)
(0.00, 0.24) −0.32 (−1.63, 0.00)
Gy (0 Gy, 1.20 Gy) −1.14 Gy (−4.00 Gy, 0.10 Gy)
ean values of the 4D inter-fraction variation are the average of the largest
Table 2 Motion effect on OAR dose distribution in fifteen patients










Dmax −0.03 Gy (−0.40 Gy, 0.20 Gy) −0.05 Gy (0.00 Gy, 0.40 Gy) −0.03 Gy (−0.30 Gy, 0.50 Gy)
D_0.35cc 0.00 Gy (−0.16 Gy, 0.17 Gy) 0.02 Gy (0.00 Gy, 0.05 Gy) 0.03 Gy (−0.12 Gy, 0.24 Gy)
D_1.2cc 0.01 Gy (−0.12 Gy, 0.14 Gy) 0.02 Gy (0.00 Gy, 0.06 Gy) 0.03 Gy (−0.13 Gy, 0.18 Gy)
Esophagus
Dmax −0.22 Gy (−1.30 Gy, 0.30 Gy) −0.19 Gy (0.00 Gy, 0.80 Gy) −0.37 Gy(−2.60 Gy, 0.30 Gy)
D_5cc −0.06 Gy (−0.83 Gy, 1.37 Gy) 0.07 Gy (0.01 Gy, 0.21 Gy) −0.16 Gy (−0.89 Gy, 0.30 Gy)
Heart
Dmax −0.51 Gy (−2.00 Gy, 0.90 Gy) 0.27 Gy (0.00 Gy, 0.80 Gy) −0.63 Gy (−2.5 Gy, 0.90 Gy)
D_15cc −0.18 Gy (−0.69 Gy, 0.92 Gy) 0.08 Gy (0.00 Gy, 0.23 Gy) −0.38 Gy (−1.54 Gy, 0.33 Gy)
Great vessels
Dmax −0.52 Gy (−1.80 Gy, 6.00 Gy) 0.19 Gy (0.00 Gy, 0.40 Gy) 0.39 Gy (−1.10 Gy, 2.00 Gy)
D_10cc −0.12 Gy (−2.44 Gy, 2.66 Gy) 0.04 Gy (0.00 Gy, 0.13 Gy) −0.03 Gy (−1.05 Gy, 0.63 Gy)
Trachea
Dmax 0.04 Gy (−2.10 Gy, 1.40 Gy) 0.03 Gy (0.00 Gy, 0.40 Gy) 0.13 Gy (0.00 Gy, 1.00 Gy)
D_10cc −0.01 Gy (−0.42 Gy, 0.19 Gy) 0.03 Gy (0.00 Gy, 0.37 Gy) 0.01 Gy (−0.08 Gy, 0.14 Gy)
Bronchus
Dmax 0.25 Gy (−2.00 Gy, 4.90 Gy) 0.37 Gy (0.00 Gy, 1.20 Gy) 0.75 Gy (−2.00 Gy, 7.80 Gy)
D_10cc −0.42 Gy (−4.10 Gy, 2.98 Gy) 0.08 Gy (0.00 Gy, 0.25 Gy) 0.30 Gy (−0.40 Gy, 1.59 Gy)
Rib
Dmax −0.58 Gy (−3.00 Gy, 1.50 Gy) 0.29 Gy (0.00 Gy, 1.20 Gy) −0.54 Gy (−1.50 Gy, 0.60 Gy)
D_1cc −0.19 Gy (−1.58 Gy, 4.64 Gy) 0.10 Gy (0.01 Gy, 0.32 Gy) −0.33 Gy (−0.99 Gy, 0.44 Gy)
Total lung
V_20Gy 0.02% (−0.87%, 0.66%) 0.02% (0.00%, 0.14%) −0.08% (−0.41% 0.15%)
D_1500cc −0.03 Gy (−0.23 Gy, 0.64 Gy) 0.01 Gy (0.00 Gy, 0.09 Gy) 0.03 Gy (−0.13 Gy, 0.74 Gy)
D_1000cc −0.03 Gy (−0.18 Gy, 0.16 Gy) 0.00 Gy (0.00 Gy, 0.02 Gy) 0.03 Gy (−0.09 Gy, 0.46 Gy)
The mean value are cumulative dose differences averaged over all patients. The mean values of the 4D inter-fraction variation are the average values of the largest
variations among four fractions over all patients.
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that calculated on the reference CT. The three pa-
tients that showed the largest difference in PTV cover-
age from the dynamic simulation were selected for
further analysis. Histograms of the maximum dose dif-
ference per fraction from all four fractions within each
voxel were generated for the PTVs and GTVs of the
three patients. In addition, histograms of the cumula-
tive dose difference between the cumulative 4D dose
and the cumulative dose without motion calculated on
the reference CT were generated for analysis. The cu-
mulative dose without motion refers to the planned
four fraction dose calculated on a single expiration
phase CT. The impact of the motion on the dose dis-
tribution can be observed from the difference between
the cumulative 4D dose and the cumulative dose with-
out motion.Validation of plan partitioning with machine Dynalog files
This study in dynamic simulation utilized the control
points defined by the patient treatment plan and the
corresponding machine delivery timestamps recorded by
machine delivery Dynalog files. In order to ensure that
the plans were partitioned correctly with respect to the
machine control point execution time, verification of the
real time MLC position as recorded on the Dynalog files
with the plan control points was performed.
Results
Difference between 3D planned dose and cumulative
4D dose
Differences in dosimetric parameters of the target and
the OARs between the initial 3D planned dose and cu-
mulative 4D dose using the constraints from RTOG
0915 were presented in the second column of Tables 1
Figure 3 The DVH comparison of the fractional dose for all four
fractions when motion was considered. Very limited differences
in dose distributions were observed from the DVHs of four fractions. Figure 5 Axial and coronal views of the dose difference with
and without motion of three patients. The colored contours
denote the GTV (magenta), PTV (black), PTV + 2 cm (red) and body
(blue). The color overlay of the dose difference range from −5.0 Gy
to 5.0 Gy.
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percentage volume in the organ or target that receives
more than x% of the prescribed dose) was on average
about 5% smaller in the cumulative 4D doses. There was
less than 1.5% difference in PTV V95%, V90%. The change
in the ratios of prescription isodose volumes V_Presp. Iso
and V_50%Presp. Iso to PTV volume V_PTV for all patients
were less than 1.00. The intermediate dose spillage rep-








Figure 4 Histogram representations of the motion effect. a) and
b) Inter-fraction interplay effect: the voxel histogram of the largest
dose differences in PTV volume and GTV volume among all four fractions
for three patients; c) and d) difference in cumulative 4D dose with and
without motion: histogram of dose differences in the PTV and GTV due
to motion. The bars represent the percentage of the voxels in the PTV or
GTV with dose differences in 0.2 Gy bins.the PTV volume) was less than 2.2 Gy in all cases. For all
OARs assessed doses, the mean differences in dosimetric
parameters were less than 1.0 Gy. The dose constraints for
all 15 patients, as specified in RTOG 0915, were main-
tained in the cumulative 4D dose.4D Inter-fraction and cumulative inter-play effect
Four single fraction DVHs of the dynamic delivery for
one representative patient were plotted in Figure 3.
There was very little variation between the DVHs for
both the targets and OARs. Inter-fraction dose variation
is summarized in column 2 of Tables 1 and 2 for all 15
patients. A mean variation of less than 1.7% for the tar-
get and 0.4 Gy for all OARs were observed in the 4D
inter-fraction variations for all patients. One patient had
a 6.9% difference in PTV V105% between fractions. The
difference between cumulative doses with and without
motion is summarized in column 3 of Tables 1 and 2.
Mean differences of less than 2.8% for the targets and
0.8 Gy for the OARs were observed in all patients.
For the three patients selected for further analysis, the
histograms of the largest dose difference per fraction in
the PTV and GTV among all four fractions were pre-
sented in Figures 4a and 4b. The histograms of dose dif-
ferences in the PTV and GTV between the cumulative
4D dose with and without motion were presented in
Figures 4c and 4d. The latter histograms represented
the cumulative dose difference and were wider than the
fractional histograms. The spatial distribution of the dose
differences was shown in Figure 5. Note that the largest
Figure 6 Verification plot to show that the planned MLC leaf positions at the control points correspond to the actual MLC leaf motion
during delivery. These data correspond to MLC leaf 32 of bank A.
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borders outside the PTV, whereas much less dose differ-
ence was observed within the PTV.
Verification of MLC control points with real-time Dynalog
files
Examination of the machine delivery log files revealed
that the delivery time varied from 127 to 185 seconds.
The maximum dose rate was 600 MU/min but the mean
dose rate was decreased to about 583 MU/min due to
MLC motion speed limits. Figure 6 showed the positions
of one MLC leaf that shadowed the tumor during plan
delivery. The MLC position corresponded well with the
planned MLC positions at the control points in real
time. The maximum deviation of the MLC leaves from
planned control points was 1.0 mm and the standard de-
viation was 0.23 mm. Such small deviations between the
planned control points and delivery control points vali-
dated the above method of using the plan MLC leaf pos-
ition in the dynamic simulation.
Discussion
The above simulation results demonstrated that the ef-
fect of motion during the delivery of SBRT using Rapi-
dArc has limited effect on the target dose coverage,
intermediate dose spillage and OARs, while a larger de-
viation was observed at the very high dose regions
within the PTV. This could be related to the dose aver-
aging effect due to tumor motion as others have ob-
served [8]. Note that even for a single fraction, the dose
deviation was small. This may be attributed to the fact
that the dose per fraction was large in lung SBRT which
in this case was more than six times the conventional
dose per fraction (12.5 Gy vs. 1.8 to 2.0 Gy). The larger
dose per fraction translated to longer treatment times
and therefore more respiratory cycles to smooth out the
dose during the delivery of each fraction. When allfractions were considered, it was observed that the effect
of motion on the dose distribution was concentrated in
the superior and inferior borders outside the PTV as
shown in Figure 5. This was because the superior and
inferior regions outside the PTV were in the radiation
field at only some phases of the breathing cycle in the
4D analysis. When the maximum exhalation phase was
chosen as the reference image, the superior border out-
side the PTV did not receive dose in the static plan but
instead accumulates dose from the other phases when
motion was considered. For early stage peripheral lung
lesions, OARs such as the heart and bronchus were not
located proximal to the target and therefore the impact
of motion on the dose was small. The deviations in dose
to the OARs were all smaller than 1.0 Gy in the dynamic
simulation. However, in patients where the target was
proximal to the critical organs, a larger heart and/or
bronchus dose variation was observed.
We also verified that the MLC control points correlated
well with the real time plan delivery with a small deviation
in MLC positions. The impact from this small difference in
actual delivery time on the dose distribution in this study
was expected to be limited in this dynamic simulation and
not clinically meaningful. However the 4D-CT image set
used in this study was from the initial simulation CT, which
might not represent the breathing pattern during the deliv-
ery. A more realistic dynamic simulation would require
real-time respiratory monitoring or online fluoroscopy dur-
ing patient treatment and is worth further study.
The results from this simulation study are in agree-
ment with previous studies investigating the inter-play
effect of VMAT lung SBRT [18,19]. While all previous
studies as well as this one confirm that the inter-play ef-
fect can be considered small or negligible as far as target
coverage is concerned, this study adds to the literature
with regards to the impact on OARs using simulated pa-
tient data. The heart, great vessels and bronchus exhibited
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to respiratory induced motion into the target region that
is not apparent when reviewing an initial plan calculated
on the average CT image set. While these OAR doses
remained well within the normal tissue constraints for the
patients used in this study, motion into the target region
should be factored into when treating a target located
proximal to these structures.
One common assumption made in these studies is that
the respiratory motion can be considered regular and re-
producible during treatment delivery. There are two
main sources of error with regards to an ITV based ap-
proach that can impact lung SBRT. The first error arises
from irregular respiratory motion in 4D-CT which re-
sults in image artifacts and therefore impacts the accur-
acy of target definition [23]. The second error is the
accuracy of the target motion envelope from a single
4D-CT scan. If a patient assumes a deeper inspiration at
the time of treatment compared to the 4D-CT scan at
the simulation, the target coverage may be compromised
during SBRT delivery. This underlines the importance of
pre-treatment verification using fiducials, cone beam CT
or other image guidance technology in lung SBRT treat-
ment delivery.
Conclusions
This study investigated the effect of motion on IMAT
SBRT plans using patient data. A detailed study of the
inter-fraction and overall motion effect on PTV and
OAR dose distributions was performed with the planned
and simulated 4D dose. PTV coverage showed negligible
effect due to motion while high dose spillage showed lar-
ger variation from perceived planned 3D dose. Limited
motion effect was observed on OAR dose distributions
except when the target volume was located near critical
organs such as heart and/or bronchus. As IMAT SBRT
is commonly employed in clinical practice, the results
from this study are encouraging in confirming adequate
dose distribution during patient treatment delivery at
least for the patients who exhibit consistent regular
breathing patterns.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
WZ and LY wrote the program to generate the partitioned plan. JS, MK, RM
and TK analyzed the 4D image motion. WZ, LY, MK and TK performed all
work related to deformable image registration. WZ, TK and YN analyzed the
results. MC, PF, RR drew the PTV and OAR contours on CT average and 4D
images. WZ, TK, MC, PF, SJ, CS, YN and RR worked on PTV definition and
motion effect results presentations. WZ and TK drafted the manuscript. All
other authors contributed to the final version of the manuscript. All authors
read and approved the final manuscript.
Author details
1Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey,
Rutgers, The State University of New Jersey, New Brunswick, NJ 08903, USA.2Department of Radiation Oncology, University of Pennsylvania, Philadelphia,
PA 19104, USA. 3Department of Radiation Oncology, Mayo Clinic, Phoenix,
Arizona 85054, USA. 4Department of Radiation Oncology, Dana-Farber
Cancer Institute/Brigham and Women’s Hospital, Boston, MA 02115, USA.
5Department of Radiation Oncology, University of Washington, Seattle, WA
98195, USA.
Received: 2 July 2014 Accepted: 30 September 2014References
1. Song DY, Kavanagh BD, Benedict SH, Schefter T: Stereotactic body
radiation therapy. Rationale, techniques, applications, and optimization.
Oncology 2004, 18(11):1419–1430.
2. Yu CX: Intensity-modulated arc therapy with dynamic multileaf
collimation: an alternative to tomotherapy. Phys Med Biol 1995,
40(9):1435–1449.
3. Verbakel WF, Senan S, Cuijpers JP, Slotman BJ, Lagerwaard FJ: Rapid
delivery of stereotactic radiotherapy for peripheral lung tumors using
volumetric intensity-modulated arcs. Radiother Oncol 2009, 93:122–124.
4. Otto K: Volumetric modulated arc therapy: IMRT in a single gantry arc.
Med Phys 2008, 35(1):310–317.
5. Navarria P, Ascolese AM, Mancosu P, Alongi F, Clerici E, Tozzi A, Iftode C,
Reggiori G, Tomatis S, Infante M, Alloisio M, Testori A, Fogliata A, Cozzi L,
Morenghi E, Scorsetti M: Volumetric modulated arc therapy with
flattening filter free (FFF) beams for stereotactic body radiation therapy
(SBRT) in patients with medically inoperable early stage non-small cell
lung cancer (NSCLC). Radiother Oncol 2013, 107(3):414–418.
6. Herbert C, Kwa W, Nakano S, James K, Moiseenko V, Wu J, Schellenberg D,
Liu M: Stereotactic body radiotherapy: volumetric modulated Arc therapy
versus 3D Non-coplanar conformal radiotherapy for the treatment of
early stage lung cancer. Technol Cancer Res Treat 2013, 12(6):511–516.
7. Kim MJ, Yeo SG, Kim ES, Min CK, Se AP: Intensity-modulated stereotactic
body radiotherapy for stage I non-small cell lung cancer. Oncol Lett 2013,
5(3):840–844.
8. McGrath SD, Matuszak MM, Yuan D, Kestin LL, Martinez AA, Grills IS:
Volumetric modulated arc therapy for delivery of hypofractionated
stereotactic lung radiotherapy: a dosimetric and treatment efficiency
analysis. Radiother Oncol 2010, 95(2):153–157.
9. Keall PJ, Mageras GS, Balter JM, Emery RS, Forster KM, Jiang SB, Kapatoes JM,
Low DA, Murphy MJ, Murray BR, Ramsey CR, Van Herk MB, Vedam SS, Wong
JW, Yorke E: The management of respiratory motion in radiation oncology,
report of AAPM Task Group 76. Med Phys 2006, 33(10):3874–3900.
10. ICRU Report 50 Prescribing, Recording and Reporting Photon Beam Therapy
tech. rep: International Commission on Radiation Units and Measurements; 1993.
11. ICRU Report 62 Prescribing, Recording and Reporting Photon Beam Therapy
(Supplement to ICRU Report 50) tech. rep: International Commission on
Radiation Units and Measurements; 1999.
12. Vedam SS, Keall PJ, Kini VR, Mostafavi H, Shukla HP, Mohan R: Acquiring a
four-dimensional computed tomography dataset using an external
respiratory signal. Phys Med Biol 2003, 48(1):45–62.
13. Bortfeld T, Jokivarsi K, Goitein M, Kung J, Jiang SB: Effects of intra-fraction
motion on IMRT dose delivery: statistical analysis and simulation.
Phys Med Biol 2002, 47(13):2203–2220.
14. Chui CS, Yorke E, Hong L: The effects of intra-fraction organ motion on
the delivery of intensity-modulated field with a multileaf collimator.
Med Phys 2003, 30(7):1736–1746.
15. Jiang SB, Pope C, Al Jarrah KM, Kung JH, Bortfeld T, Chen GT:
An experimental investigation on intra-fractional organ motion effects in
lung IMRT treatments. Phys Med Biol 2003, 48(12):1773–1784.
16. Schaefer M, Munter MW, Thilmann C, Sterzing F, Haering P, Combs SE,
Debus J: Influence of intrafractional breathing movement in step-and-
shoot IMRT. Phys Med Biol 2004, 49(12):15–19.
17. Court LE, Seco J, Lu XQ, Ebe K, Mayo C, Ionascu D, Winey B, Giakoumakis N,
Aristophanous M, Berbeco R, Rottman J, Bogdanov M, Schofield D, Lingos T:
Use of a realistic breathing lung phantom to evaluate dose delivery
errors Med. Phys 2010, 37(11):5850–5857.
18. Ong C, Verbakel WF, Cuijpers JP, Slotman BJ, Senan S: Dosimetric impact of
interplay effect on RapidArc lung stereotactic treatment delivery. Int J
Radiat Oncol Biol Phys 2011, 79(1):305–311.
Zou et al. Radiation Oncology 2014, 9:225 Page 9 of 9
http://www.ro-journal.com/content/9/1/22519. Stambaugh C, Nelms BE, Dilling T, Stevens C, Latifi K, Zhang G, Moros E,
Feygelman V: Experimentally studied dynamic dose interplay does not
meaningfully affect target dose in VMAT SBRT lung treatments. Med Phys
2013, 40(9):1710–1718.
20. Kuo HC, Mah D, Chuang KS, Wu A, Hong L, Yaparpalvi R, Spierer M, Kalnicki
S: A method incorporating 4DCT data for evaluating the dosimetric
effects of respiratory motion in single-arc IMAT. Phys Med Biol 2010,
55(12):3479–3497.
21. Rao M, Wu J, Cao D, Wong T, Mehta V, Shepard D, Ye J: Dosimetric Impact
of Breathing Motion in Lung Stereotactic Body Radiotherapy Treatment
Using Image-Modulated Radiotherapy and Volumetric Modulated Arc
Therapy. Int J Radiat Oncol Biol Phys 2012, 83(2):251–256.
22. RTOG 0915: A randomized phase II study comparing 2 stereotactic body
radiation therapy (SBRT) schedules for medically inoperable patients with stage
I peripheral mon-small cell lung cancer; 2009.
23. Sarker J, Chu A, Mui K: Variations in tumor size and position due to
irregular breathing in 4D-CT: a simulation study. Med Phys 2010,
37(3):1254–1260.
doi:10.1186/s13014-014-0225-3
Cite this article as: Zou et al.: Dynamic simulation of motion effects in
IMAT lung SBRT. Radiation Oncology 2014 9:225.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
